A new paper released by NACDS and prepared by PricewaterhouseCoopers has identified the following four steps for successful new product launches.
A new paper released by NACDS and prepared by PricewaterhouseCoopers has identified the following four steps for successful new product launches:
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.